Assessment of lower urinary tract symptoms among calcium channel blocker-users and its impact on quality of life Authors Muhammad Salman Department of Pharmacy, The University of Lahore, Lahore, Pakistan Amer Hayat Khan Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia Syed Azhar Syed Sulaiman Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia Jeffery David Hughes School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia Junaid Habib Khan National Hospital and Medical Center, Lahore, Pakistan Naureen Shehzadi Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan Khalid Hussain Punjab University College of Pharmacy, University of the Punjab, Lahore, Pakistan DOI: https://doi.org/10.47391/JPMA.1162 Abstract Objective: to investigate the prevalence and severity of lower urinary tract symptoms (LUTS) among calcium channel blocker (CCB) users and its impact on patients’ quality of life (QOL) Methods: This cross-sectional study was conducted among CCB-users, recruited using convenience sampling, at one hospital and 2 community pharmacies at Lahore, Pakistan during November 2017-July 2018. Urdu version of the International Prostate Symptom Score (IPSS) and EQ-5D-3L were used to assess LUTS and QOL, respectively. All data were entered and analyzed using SPSS version 22.Results: The median age of the study participants (N = 410) was 50.84, with majority of males. Around 26% of study participants were on CCB monotherapy whereas 73.7% were on CCB combinations with other antihypertensive agents. Overall prevalence of LUTS was 74.9%, with storage symptoms more common than voiding. The most common troublesome symptom was nocturia (89.5%) followed by increased daytime urinary frequency (87.1%). Median IPSS-QOL index, EQ-5D index and EQVAS score in our participants were 3, 0.621 and 60, respectively. Moreover, LUTS were significantly associated with reduced QOL (mean rank IPSS QOL-index: none-mild = 156.76 and moderate-severe = 221.85, p < 0.001; median EQ 5D index; none-mild = 0.796 and moderate-severe = 0.416; mean rank EQ-VAS: none-mild = 228.51, moderate-severe = 197.78, p = 0.022).Conclusion: Around 75% of CCB-users suffer from clinically significant LUTS which is associated with significant reduction in patient’s QOL. An earlier detection and management of LUTS by healthcare provider among CCB-users may and improve the overall QOL. Continuous... Downloads Full Text Article Published 2021-12-29 How to Cite Muhammad Salman, Amer Hayat Khan, Syed Azhar Syed Sulaiman, Jeffery David Hughes, Junaid Habib Khan, Naureen Shehzadi, & Khalid Hussain. (2021). Assessment of lower urinary tract symptoms among calcium channel blocker-users and its impact on quality of life. Journal of the Pakistan Medical Association, 71(5), 1384–1387. https://doi.org/10.47391/JPMA.1162 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 71 No. 5 (2021): MAY Section RESEARCH ARTICLE